The polymorphic variant rs9364554 (c.582 + 1786C>T) is associated with decreased OCT3 expression in prostate cancer [161], whereas the common variant g.-2G>A (rs555754) has been associated with a higher level of OCT3 expression [159]. Here, SLC22A3 is linked to prostate cancer.